Apomine, a novel 1,1-bisphosphonate ester, has been shown to lower plasma cholesterol concentration in several species. Here we show that Apomine reduced the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the rate-limiting enzyme in the mevalonate pathway, both in rat liver and in cultured cells. Apomine resembles sterols such as 25-hydroxycholesterol in its ability to potently accelerate the rate of HMGR degradation by the ubiquitin-proteasome pathway, a process that depends on the transmembrane domain of the enzyme. The similarity between Apomine and sterols in promoting rapid HMGR degradation extends to its acute requirements for ongoing protein synthesis and mevalonate-derived non-sterol product(s) as a co-regulator. Yet, at suboptimal concentrations, sterols potentiated the effect of Apomine in stimulating HMGR degradation, indicating that these agents act via distinct modes. Furthermore, unlike sterols, Apomine inhibited the activity of acyl-CoA:cholesterol acyltransferase in intact cells but not in cell-free extracts. Apomine stimulated the cleavage of the precursor of sterolregulatory element-binding protein-2 and increased the activity of low density lipoprotein receptor pathway. This Apomine-enhanced activation of sterol-regulatory element-binding protein-2 was prevented by sterols or mevalonate. Taken together, our results provide a molecular mechanism for the hypocholesterolemic activity of Apomine.
In mammalian cells, cholesterol homeostasis is maintained by balancing cholesterol uptake and production. Cholesterol uptake is regulated through modulating the levels of the cell surface low density lipoprotein (LDL) 1 receptor (LDLR), and cholesterol synthesis is regulated primarily by changes in levels and activity of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) (1, 2) . HMGR is an endoplasmic reticulum (ER) enzyme that catalyzes the conversion of 3-hydroxy-3-methylglutaryl-CoA into mevalonate (MVA), the first committed step in the MVA pathway that leads to the synthesis of cholesterol as well as of essential non-sterol isoprenoid compounds (1, 2) . When cells are starved for cholesterol and/or MVA, levels of HMGR and LDLR are elevated, thus increasing the rate of endogenous sterol synthesis and of LDL uptake (3, 4) . Conversely, in cholesterol-replete cells, the levels of HMGR and LDLR decline, thereby lowering sterol production and LDL internalization.
HMGR and LDLR are regulated at the transcriptional level by sterol-regulatory elements (SREs) in the promoter of their genes (1, 5) . Specific transcription factors, designated SREbinding proteins (SREBPs), bind to these elements and activate transcription (5, 6) . The SREBP family comprises three members that control different sets of genes. SREBP-2 regulates the transcription of genes mainly involved in sterol synthesis, whereas SREBP-1a and -1c regulate principally fatty acid biosynthetic genes (7) . The nuclear, transcriptionally active SREBPs are derived from the NH 2 -terminal domain of large ER membrane-bound precursors through sequential proteolytic cleavage by the two Golgi proteases, Site-1 protease and Site-2 protease (8) . In sterol-depleted cells, the membrane SREBP precursors are transported by vesicles to the Golgi where cleavage occurs, generating soluble transcription factors that enter the nucleus and activate transcription of target genes (9 -11) . When sterols are abundant, or when cells are treated with potent hydroxylated forms of cholesterol such as 25-hydroxycholesterol, the voyage of the SREBP precursors from the ER to the Golgi is prevented (9) , and consequently the levels of the nuclear SREBPs decrease (12) , and transcription of SRE-controlled genes declines. The SREBP cleavage-activating protein (SCAP), a polytopic ER protein with sterol-sensing domain, plays a critical role in SREBP activation as it escorts the SREBP precursors from the ER to the Golgi in steroldepleted cells (13) (14) (15) . In the presence of sterols, the SCAP⅐SREBP complex is retained in the ER through binding of SCAP to resident ER membrane proteins Insig-1 and/or Insig-2, thus preventing SREBPs from reaching the compartment where the cleaving proteases reside (16, 17) . This is the feedback mechanism by which sterols are believed to regulate transcription of SRE-controlled genes.
Sterols and MVA-derived non-sterol products regulate HMGR levels also at the posttranslational level by controlling the rate of degradation of the enzyme (18 -20) . In cells that have been depleted of cholesterol and/or MVA, HMGR is quite stable, but when cells are supplemented with sterols, such as 25-hydroxycholesterol, or with excess MVA, the enzyme is rapidly degraded (20, 21) . This conditional degradation of HMGR appears to be carried out by an otherwise constitutive quality control process known as ER-associated degradation, which eliminates aberrant proteins in the secretory pathway (22, 23) . Similar to other ER-associated degradation substrates, HMGR is degraded by the ubiquitin-proteasome system. However, HMGR sets a special example for a normal ER membrane protein that is tagged by multiubiquitin chains and degraded by the proteasome in a metabolically regulated manner (23, 24) . The structural element in HMGR that confers the regulated turnover is its multispan membrane-embedded portion (25) , which, like SCAP, also contains a sterol-sensing domain (13) . When grafted onto other proteins, such as ␤-galactosidase, this transmembrane domain endows the resulting fusion protein, HMGal, with both ER localization and metabolically controlled degradation (26 -28) . Recent data indicate that Insig-1 is also crucial for the sterol-regulated degradation of HMGR (29) .
The central role of the MVA pathway in normal and pathological cell physiology has been demonstrated in multiple studies in which MVA production was blocked by a class of HMGR competitive inhibitors collectively known as statins. The inhibition by statins of endogenous cholesterol synthesis and the resulting increase in LDLR expression have been exploited to lower plasma cholesterol levels in hypercholesterolemia. However, there is a growing body of evidence that statins possess pleiotropic effects, which appear to be unrelated to their hypocholesterolemic activity. Therefore, new indications for the use of statins have been suggested, including treatment of osteoporosis (30) and Alzheimer's disease (31) , although the efficacy of statins in the treatment of such conditions has not been demonstrated. It is well accepted that statins mainly target the liver and are poorly bioavailable systemically when given orally. Furthermore experiments in animal models, as well as clinical studies in humans, have shown that systemic exposure of tissues other than liver to this class of HMGR inhibitors results in a significant toxicity. Thus, although the MVA pathway appears to hold a great potential as a target for multiple pharmacological interventions, attempts to develop new classes of drugs that impair HMGR activity by decreasing HMGR mRNA or by increasing the degradation rate of the enzyme have not been exploited.
We discovered a new class of synthetic hypocholesterolemic compounds, the 1,1-bisphosphonate esters, that are not competitive inhibitors of HMGR. A representative of this class of compounds, SR-12813, has been shown to inhibit the MVA pathway in HepG2 cells by increasing the rate of HMGR degradation (54) . The resulting decrease in cholesterol synthesis, which was also observed in vivo in dogs that were orally administered with SR-12813, leads to hypocholesterolemia. A more potent analogue, SR-45023A (Apomine TM , see Fig. 1 ), is currently under clinical trials. Here we investigate the mechanism(s) by which Apomine exerts its hypocholesterolemic activity and show that it increases the rate of HMGR degradation in cultured cells and decreases HMGR levels in rat liver. Comparative studies reveal that the mechanism by which Apomine leads to the decrease in HMGR protein levels resembles the one displayed by 25-hydroxycholesterol. However, unlike 25-hydroxycholesterol but similar to Simvastatin, Apomine induces cleavage of SREBP-2 and increases LDL receptor expression. Our results provide a molecular mechanism for the hypocholesterolemic activity of Apomine.
EXPERIMENTAL PROCEDURES
Materials-Unless otherwise noted, all reagents were obtained from Sigma. Mevalonolactone (Fluka) was converted to the sodium salt. Antibodies-HMGR and HMGal were immunoprecipitated with specific antiserum directed against the membrane domain of HMGR (34) , and HMGR was detected by immunoblotting using mouse A9 monoclonal antibody (35) . In some experiments, HMGal was immunoprecipitated with an anti ␤-galactosidase antibody (Promega). Mouse IgG-1C6 monoclonal antibody (Pharmingen) was used in immunoblotting analysis of SREBP-2. Polyubiquitin conjugates were detected with a monoclonal antibody from Santa Cruz Biotechnology (clone P4D1). Horseradish peroxidase coupled to goat anti-mouse or anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories.
Cells-All cells were maintained at 37°C in a 5% CO 2 atmosphere in a humidified incubator. CHO cells were grown in Medium A (minimal essential medium supplemented with 5% FCS, 2 mM glutamine, 100 units/ml penicillin, 100 g/ml streptomycin). LP-90 cells (36) were kept in Medium B (Medium A in which LPDS was substituted for FCS and also supplemented with 90 M lovastatin). UT2-HMGal cells were generated through stable transfection of UT2 cells (37) with pHMGal-Neo plasmid (36) . These cells were maintained in Medium A supplemented with 0.2 mM MVA and 250 g/ml Geneticin. To up-regulate expression of HMGR and LDLR, the cells were grown for 16 -20 h in LPDS medium (in which LPDS was substituted for FCS and which was also supplemented with 2 M compactin and 100 M MVA). HeLa cells were grown in Hepes-buffered high glucose Dulbecco's modified Eagle's medium supplemented with 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. These cells were up-regulated by omitting the serum from their growth medium. Where indicated, sterols were added in ethanol to final concentrations of 2 g/ml 25-hydroxycholesterol plus 20 g/ml cholesterol, and MVA was added to a final concentration of 20 mM. Apomine was dissolved in Me 2 SO/ethanol (1:1, v/v).
Metabolic Labeling and Immunoprecipitation-On day 1, 8 ϫ 10 5 CHO cells were plated in Medium A in 60-mm dishes. On day 2, cells were refed with LPDS-containing medium supplemented with 2 M compactin and 100 M MVA. On day 3, the cells were starved for 1 h in 1 ml of methionine-and cysteine-free minimal essential medium containing 5% LPDS, 2 M compactin, and 100 M MVA. The cells were then pulse-labeled for 30 min with 100 -150 Ci of protein labeling mixture and chased in LPDS medium supplemented with 2 mM methionine and the indicated additions. At the indicated time points, cells were lysed and processed for immunoprecipitation with the indicated antibodies as described previously (21) . Samples were resolved by 5-15% SDS-PAGE.
Immunoblotting-Proteins were electroblotted onto Optitran BAS-83 reinforced nitrocellulose (Schleicher & Schuell), and the membranes were probed with the appropriate primary and horseradish peroxidaseconjugated secondary antibodies followed by enhanced chemiluminescence reaction.
Measurement of Acyl-CoA:Cholesterol Acyltransferase (ACAT) Activity-ACAT activity in cultured cells was assayed, with minor modifications, as described in Ref. 38 . Briefly, on day 1, CHO or HeLa cells were plated in 12-well plates (2 ϫ 10 5 cells/well) and up-regulated on day 2 as described above. On day 3, the medium was aspirated, and the cells were refed with 1 ml of fresh medium into which 2 g/ml 25-hydroxycholesterol plus 20 g/ml cholesterol (in ethanol) or 80 g/ml LDL were added in the absence or presence of 1 M Apomine. After 5 h of incubation at 37°C, [ 3 H]oleate (complexed to bovine serum albumin) was added to a final concentration of 100 M (40,000 dpm/nmol), and the cells were labeled for an additional 2 h. The cells were then washed in phosphate-buffered saline and extracted twice with 2 ml of hexane/ isopropanol (3:2, v/v). After addition of unlabeled cholesteryl oleate as a carrier, the pooled extracts were dried under N 2 . Lipids were resolved by thin layer chromatography on plastic-backed silica gel plates using petroleum ether/diethyl ether/acetic acid (80:20:1, v/v) as the solvent system. The spot containing cholesteryl oleate (R F , 0.8) was cut out and counted by liquid scintillation.
To measure ACAT activity in cell-free extracts, on day 1 cells were plated at a density of 4 ϫ 10 6 /100-mm dishes in their respective FCScontaining media. The media were changed 2 h before the cells were harvested on day 2. Cell extracts were prepared by the hypotonic shock and scraping method (39) and were adjusted to 50 mM Tris-HCl, pH 7.8. Assay tubes consisted of 120 l of 75 mM Tris-HCl, pH 7.8 containing ϳ200 g of protein and 100 M [
14 C]oleoyl-CoA complexed to bovine serum albumin (ϳ8,000 dpm/nmol). Tested compounds dissolved in Me 2 SO/ethanol (1:1, v/v) were added directly to the assay mixtures such that solvent concentrations did not exceed 1%. The tubes were incubated at 37°C for 30 min, and reactions were terminated by adding 3 ml of chloroform/methanol (2:1, v/v) and unlabeled cholesteryl oleate as a carrier. After addition of 1 ml of water, phases were separated by low speed centrifugation. The organic phase was evaporated under N 2 , and lipids were resolved by thin layer chromatography as described above.
Degradation of 125 I-LDL-On day 1, 1 ϫ 10 5 CHO cells were plated in 24-well dishes in Medium A. On day 2, cells were refed with LPDS medium in the absence or presence of sterols (2 g/ml 25-hydroxycholesterol and 20 g/ml cholesterol) or 1 M Apomine. On day 3, quadruplicate wells received 125 I-LDL at 10 g/ml (250 -650 cpm/ng) in the absence or presence of 400 g/ml unlabeled LDL. Following incubation at 37°C for 5 h, the amount of trichloroacetic acid-soluble 125 I radioactivity was determined as described previously (32) .
Animal Experiments-Male Wistar rats (230 -270 g, Charles River Iffa-Credo, L'Arbresle, France) were housed in groups of four animals/ cage and subjected to a cycle of 12 h of light and 12 h of dark. All animals were fed standard diet (UAR AO3). Treatment was administered by oral gavage. The animals were anesthetized with 60 mg/kg intraperitoneal pentobarbital (Vetanarcol, Veterinaria, Zü rich, Switzerland) and sacrificed. Liver samples were immediately frozen in liquid nitrogen and kept at Ϫ80°C until analysis. Frozen tissues were rapidly homogenized in lysis buffer (20 mM Hepes, pH 7.4, 50 mM NaCl, 10 mM EDTA, 10 mM EGTA, 1% Triton X-100, protease inhibitor mixture (Complete, Roche Applied Science)) using an Ultraturax device. The lysates were centrifuged for 30 min at 7,000 ϫ g, and the supernatants were analyzed for HMGR by immunoblotting.
Miscellaneous Methods-HMGal activity was measured by the hydrolysis of o-nitrophenyl ␤-D-galactopyranoside in digitonin-permeabilized cells as described previously (26) . Protein content was measured with the micro-BCA reagent from Pierce or by the Folin phenol method (40) .
RESULTS
Apomine Accelerates the Degradation of HMGR-The structure of Apomine is shown in Fig. 1 . Since previous studies have demonstrated that Apomine treatment leads to hypocholesterolemia in animals (41), we examined its effect on HMGR levels in rat liver. Rats were treated with Simvastatin or with vehicle for 4 days and then given a single dose of Apomine. Five hours later, liver homogenates were prepared, and HMGR levels were analyzed and quantified by immunoblotting with anti-HMGR monoclonal antibody. As shown in Fig. 2A , Simvastatin drastically elevated the levels of the enzyme (Ͼ530%) when compared with vehicle-treated rats. Apomine treatment decreased HMGR levels by 22%. Remarkably a single dose of Apomine nearly halved the elevated levels of HMGR in Simvastatintreated animals, lowering it by 45% (Fig. 2A) . Fig. 2B shows that the effect of Apomine on HMGR levels is recapitulated in cultured cells. HeLa cells were treated for 5 h with increasing concentrations of Apomine, and the levels of HMGR in equal amounts of total cell protein were assessed. As shown, Apomine caused a dose-dependent decrease in HMGR levels with an estimated IC 50 of ϳ100 nM (Fig. 2B) . Next we tested whether this decrease in HMGR resulted from alterations in the enzyme stability (Fig. 2C) . To this end, we used the lovastatin-resistant LP-90 cells, which overproduce HMGR but normally control its levels through regulated turnover (36) . Cells were pulse-labeled with 35 S-labeled amino acids and chased for the indicated times in the absence or presence of sterols or increasing concentrations of Apomine. As shown, Apomine shortened the half-life of HMGR in LP-90 cells in a dose-dependent manner with an estimated IC 50 of ϳ10 nM. The maximal effect of 5-fold accelerated HMGR degradation was attained at 100 nM Apomine, similar to the stimulation achieved by saturating amounts of sterols (Fig. 2C) . We also examined the effect of Apomine in untransfected CHO cells or in UT2 cells that were stably transfected with HMGal, a fusion protein composed of the membrane domain of HMGR and bacterial ␤-galactosidase (26) (Fig. 2D) . As assessed by pulse-chase and immunoprecipitation, Apomine accelerated the degradation of HMGR in CHO cells and of HMGal in UT2 cells (Fig. 2D, inset) . Increased degradation rate of HMGal was also evident by its enzymatic activity, which decreased in a dose-dependent manner with an apparent IC 50 of Ϸ250 nM Apomine (Fig. 2D) . A nearly maximal effect was achieved at 1 M, and a 90% decline in activity was observed at 5 M Apomine. For comparison, only a ϳ60% decrease in HMGal activity was achieved by a mixture of sterols containing the same concentration of 25-hydroxycholesterol (2 g/ml, ϳ5 M). Taken together, these results demonstrate that Apomine resembles sterols in its ability to accelerate the degradation of HMGR by a process that is directly mediated through the transmembrane domain of the enzyme and neither requires the catalytic domain nor the enzymatic activity of reductase. Consistent with the rapid loss of HMGR protein and activity from the cells, Apomine inhibited the synthesis of cholesterol from [ 14 C]acetate, similar to the effect observed in cells treated with Simvastatin, a competitive inhibitor of HMGR (Table I) .
Apomine-accelerated Degradation of HMGR Requires Nonsterol MVA-derived Metabolite(s)-It has been shown that rapid degradation of HMGR can be induced by treating cells either with high concentrations of MVA or with sterols (18, 20, 21, 25, 36, 42, 43) . However, while MVA provides cells with both sterol and non-sterol metabolites that promote HMGR degradation, one of the hallmarks of the sterol-accelerated degradation is that it does not occur in cells that are depleted of MVA. It indicates that MVA-derived non-sterol(s) are absolutely required in sterol signaling for HMGR elimination (20, 21) . Previous studies suggested that farnesyl diphosphate, or the farnesyl diphosphate-derived free alcohol farnesol, may play the role of the non-sterol regulators in HMGR degradation (23, 44 -48) . To test whether the effect of Apomine resembled the MVA-accelerated or the sterol-induced HMGR degradation, we first assessed whether zaragozic acid (49), a specific inhibitor of squalene synthase, affected Apomine-stimulated HMGR degradation. Fig. 3 shows that blocking squalene synthase activity, which increases the intracellular levels of farnesyl diphosphate and/or farnesol (49), did not impair the accelerated degradation exerted by either Apomine or sterols. However, as expected, zaragozic acid inhibited the fast turnover of HMGR in response to high concentrations of MVA. Therefore, if farnesyl diphosphate/farnesol is indeed the non-sterol co-regulator for both the sterol-and the Apomine-accelerated degradations, its intracellular levels are not limiting under our experimental conditions.
To test whether Apomine resembles sterols in the requirement for a MVA-derived metabolite, we utilized UT2-HMGal cells because these cells lack endogenous HMGR and, thus, can be totally depleted of MVA. Nevertheless these cells are fully capable of regulating the degradation of transfected HMGR (25) or HMGal (21) . Cells were incubated for 16 h in a MVAdeficient medium that was also supplemented with 20 M lovastatin to block any residual HMGR activity that may potentially be present (50) . The cells were then further incubated for 12 h in the absence or presence of 1 mM MVA with sterols or with increasing concentrations of Apomine. Measurements of HMGal activity revealed that in the absence of MVA, Apomine decreased HMGal activity by only 25%, whereas in the presence of MVA, HMGal activity declined by more than 75% (Fig.  4) . In comparison, sterols decreased HMGal activity by only 15% in the absence of MVA but by more than 65% in MVA presence. Indeed pulse-chase and immunoprecipitation experiments directly confirmed that in the absence of MVA, both sterols and Apomine were much less effective in accelerating the degradation of HMGal (Fig. 4, inset) . Thus, the presence of a minute amount of MVA, which by itself did not promote HMGal degradation, was necessary and sufficient to support the activity of either Apomine or sterols in promoting the rapid elimination of HMGal. Taken together with the results shown in Fig. 3 , our data demonstrate that the putative MVA-derived non-sterol metabolite(s) is obligatory for the Apomine-acceler-
FIG. 2. Apomine accelerates degradation of HMGR.
A, groups of four adult male rats were either treated (Sim) or not (Con) for 4 days with 100 mg/kg Simvastatin. On day 5, animals were administered with 100 mg/kg Apomine (Apo) or vehicle as indicated. Five hours later, the rats were sacrificed, liver homogenates were prepared, and HMGR levels were analyzed by immunoblotting as described under "Experimental Procedures." B, HeLa cells were treated with the indicated concentrations of Apomine for 5 h. Cell lysates were analyzed for HMGR by immunoblotting (inset), and HMGR levels were quantified by densitometric scanning of the blot. C, LP-90 cells were pulse-labeled and chased in the absence or presence of sterols or the indicated concentrations of Apomine as described under "Experimental Procedures." At the indicated time points, cells were lysed, and HMGR was immunoprecipitated. HMGR bands (inset) were quantified by densitometry, and HMGR half-life was calculated and plotted as a function of Apomine concentration (q) or sterols (f) where "100%" is the half-life of HMGR with no additions (8 h). D, UT2-HMGal cells were treated for 14 h with Apomine (q) or sterols (f), and ␤-galactosidase activity of HMGal was measured. Inset, CHO cells (lanes 1-8) or UT2-HMGal cells (lanes 9 -16) were pulse-labeled (P, lanes 1, 8, 9 , and 16) and chased for 6 h in the presence of sterols (ST) or the indicated concentrations of Apomine. HMGR and HMGal were immunoprecipitated with an antibody directed against their common membrane domain. ated turnover of HMGR as it is for the sterol-promoted process. Moreover this non-sterol co-regulator for Apomine-accelerated HMGR degradation originates from the MVA pathway upstream of the step catalyzed by squalene synthase.
Apomine-accelerated Degradation of HMGR Requires Ongoing Protein Synthesis and Is Mediated by the Ubiquitin-Proteasome Pathway-To further explore the resemblance between
Apomine and sterols, we tested whether the Apomine-accelerated degradation also required ongoing protein synthesis (21, 24, 42) . As can be seen in Fig. 5 , when pulse-labeled cells are chased in the presence of cycloheximide, the rapid degradation of HMGR evoked by either sterols or Apomine is severely impaired, indicating that short-lived protein(s) is involved in HMGR degradation regardless of whether the signaling molecules are Apomine or sterols.
It has recently been demonstrated that the rapid degradation of mammalian HMGR in response to sterols is mediated by the ubiquitin-proteasome pathway (24) . To examine whether this pathway also executed the Apomine-accelerated degradation, CHO cells were treated for 2 h with sterols or Apomine in the absence or presence of the proteasome inhibitor MG-132. HMGR was immunoprecipitated and analyzed by immunoblotting with anti-ubiquitin antibodies. As shown in Fig. 6 (top  panel) , addition of either sterols or Apomine markedly increased the levels of the ubiquitin-reactive material that precipitated with anti-HMGR antibodies (Fig. 6, top panel) . Notably this material originated from the 97-kDa HMGR and migrated as a closely spaced set of bands that smeared toward the top of the gel (Fig. 6, top panel, lanes 3 and 5, respectively) . Concomitantly there was a significant decrease in the levels of HMGR protein itself (Fig. 6, bottom panel, lanes 3 and 5, respectively) relative to untreated cells (Fig. 6, bottom panel,  lane 1) . Inhibition of the proteasome with MG-132 further increased the amounts of polyubiquitin-conjugated HMGR in both sterol-or Apomine-treated cells (Fig. 6, top panel, lanes 4  and 6, respectively) , but the actual amounts of HMGR protein did not change relative to the untreated cells (Fig. 6 , bottom panel, lanes 4 and 6, respectively; compare with lane 1). Thus, Apomine mimics sterols in its ability to signal for the rapid elimination of HMGR by the ubiquitin-proteasome pathway.
Apomine Neither Acts as a Sterol in Acceleration of HMGR Degradation nor Promotes Cholesterol Mobilization to the ER-
The similarities between Apomine and sterols in accelerating HMGR turnover raised the possibility that Apomine functions indirectly by mobilizing sterols from intracellular pools to the ER, which, in turn, signal for rapid HMGR degradation. To explore this possibility, LP-90 cells were pulse-labeled and chased in the presence of increasing concentrations of both Apomine and sterols. After a 5-h chase, HMGR was immunoprecipitated (Fig. 7, top panel) and quantified by densitometry, setting the remaining levels of HMGR at the end of the chase in the absence of either compound as "0% HMGR degraded" (Fig.  7, bottom panels A and B) . As can be clearly seen, the amounts of HMGR degraded at increasing concentrations of Apomine plateaued to a different level depending on the concentration of sterols. Under these conditions, the maximal value of ϳ75% of HMGR degraded was attained at saturating concentrations of both agents (Fig. 7A ). Plotting these data with sterol concentrations on the abscissa exhibits a very similar response (Fig.  7B ). These results demonstrate that at maximal effective concentrations of sterols or Apomine these agents are still capable to potentiate the effects of one another. This indicates that, despite their apparent similarities, sterols and Apomine function in the degradation of HMGR in distinct modes.
To monitor possible mobilization of sterols to the ER by a different method, we examined the effect of Apomine on ACAT, an ER enzyme whose activity is stimulated in response to expansion of ER cholesterol pools (51) . Sterol-depleted CHO and HeLa cells were incubated with ethanol-dissolved sterols or with isolated LDL fraction in the absence or presence of Apomine. Following 5 h of incubation, the cells were pulsed labeled for 2 h with [ 3 H]oleic acid. Total cellular lipids were extracted and resolved by thin layer chromatography, and the amount of [ 3 H]cholesteryl oleate formed was determined (Table  II) . In CHO cells receiving neither LDL nor sterols, ACAT activity was inhibited 34% by 1 M Apomine. Addition of sterols to the cells stimulated the production of cholesteryl oleate 3.5-fold, and Apomine inhibited this activity by ϳ40%. Upon addition of LDL, ACAT activity rose Ͼ15-fold, yet Apomine consistently inhibited ACAT by less than 10% (Table II) . In control experiments, the Sandoz compound 58-035 (at 3 g/ml), a well established competitive inhibitor of ACAT (52) , inhibited the LDL-and sterol-stimulated ACAT activity in CHO cells by 95 and 80%, respectively (data not shown). Somewhat different results were obtained with HeLa cells where Apomine decreased the sterol-or LDL-stimulated ACAT activity by ϳ30% relative to untreated cells (Table II) . Nevertheless, in both cell lines, Apomine noticeably inhibited ACAT activity. Importantly Apomine did not directly inhibit ACAT activity in CHOderived cell-free extracts and had only a marginal effect on ACAT in HeLa cell homogenates (Table III) . Together these results indicate that Apomine does not act by mobilizing sterols to the ER. Apomine Increases LDLR Activity-Next we examined the effect of Apomine on other aspects of cellular cholesterol homeostasis, such as regulation of LDLR activity. CHO cells maintained in LPDS medium were treated for 16 h with either Apomine or sterols, and then 125 I-labeled LDL was added. Following 5 h of incubation at 37°C, the amount of degraded 125 I-LDL was determined by measuring trichloroacetic acidsoluble 125 I radioactivity released to the medium. As shown in Table IV , Apomine increased the rate of LDL degradation by an average of 65%, whereas sterols inhibited LDLR activity by 77%.
Apomine Induces SREBP-2 Cleavage-The observation that Apomine elevated LDLR activity could reflect the transcriptional activation of the LDLR gene through the proteolytic cleavage of SREBPs. We directly studied whether Apomine triggers SREBP processing. HeLa cells were incubated with different concentrations of Apomine or Simvastatin in the absence or presence of 25-hydroxycholesterol or MVA. Cell lysates were prepared and analyzed by immunoblotting with the IgG-1C6 monoclonal antibody (Fig. 8) . This antibody recognizes the COOH terminus of SREBP-2, which remains membrane-bound after the release and transport to the nucleus of the mature, transcriptionally active NH 2 -terminal soluble domain of SREBP-2. Nevertheless the levels of this COOH-terminal cleavage product provide a faithful readout for the sterol-regulated proteolytic activation of SREBP-2 (53). In cells maintained in serum-containing medium, no cleavage product is seen (Fig. 8, A and B, lane 1, FCS) . Incubating the cells in the absence of serum resulted in generation of a significant amount of SREBP-2 cleavage product (Fig. 8, A and B, lane 2) . Under these conditions, treating the cells with Simvastatin further increased the cleavage of SREBP-2 precursor (Fig. 8, A, lanes 6  and 7, and B, lanes 3 and 4) . Notably Apomine also markedly enhanced the proteolytic activation of SREBP-2 (Fig. 8, A, lanes  3-5, and B, lanes 5-7) . Significantly the processing of the SREBP-2 precursor and generation of the COOH-terminal fragment was inhibited when the cells received 25-hydroxycholesterol (Fig. 8A, lanes 8 -19) or high concentrations of MVA (Fig. 8B, lanes 8 -13) . These results demonstrate that the augmented activation of SREBP-2 by Apomine is the result of profound depletion of cellular MVA and sterols, probably due to the accelerated degradation of HMGR.
DISCUSSION
Apomine, like other members of the family of 1,1-bisphosphonate esters, has been shown to lower plasma cholesterol levels in several animal species (41) . The current experiments were undertaken to study the mode of action of Apomine. We show that Apomine decreases the levels of HMGR in cultured cells as well as in rat liver and reduces endogenous cholesterol synthesis in the MVA pathway. Moreover Apomine causes a substantial increase in activity of the LDLR pathway and hence accelerates clearance of LDL-borne cholesterol. Combined these effects are likely to explain the potent hypocholesterolemic properties of Apomine.
Apomine, as its closely related analog SR-12813 (54), lowers the steady-state levels of HMGR by promoting its rapid turnover. Our data demonstrate that this Apomine-accelerated degradation neither requires HMGR catalytic activity nor involves its cytoplasmic domain. Rather this process entirely depends on the membrane-spanning region of HMGR, requires ongoing protein synthesis, and is mediated by the ubiquitin-proteasome pathway as the proteolytic machinery to eliminate this enzyme. In this regard, Apomine appears to mimic 25-hydroxycholesterol, a potent sterol stimulator of HMGR degradation. Importantly, although Apomine resembles 25-hydroxycholesterol in its absolute requirement for a MVA-derived metabolite(s) as co-regulator(s), these agents appear to utilize distinct modes to signal for HMGR destruction. Moreover Apomine has an effect opposite to that of 25-hydroxycholesterol on the processing of SREBP; while 25-hydroxycholesterol inhibits SREBP proteolytic activation, Apomine markedly stimulates the cleavage of SREBP-2 precursor similar to Simvastatin. This is a likely outcome of the diminishing intracellular MVA production and cholesterol synthesis due to the eradication of HMGR protein in the case of Apomine or inhibition of HMGR enzymatic activity in the case of Simvastatin. This activity of Apomine is probably responsible for the increased LDLR activity.
It has been suggested that 25-hydroxycholesterol inhibits SREBP processing by promoting translocation of cholesterol from the plasma membrane to the ER where it interacts with the sterol-sensing domain of SCAP and causes conformational changes that induce its binding to the ER-resident Insig proteins (16, 55) . It is postulated that this tight association with Insigs prevents the SCAP⅐SREBP complex from leaving the ER (16, 17) . Therefore, the activation of SREBP cleavage by Apomine, demonstrated in this study, suggests that Apomine weakens the interaction between the Insig(s) and SCAP⅐SREBP complex, allowing the egress of the latter from the ER en route to the Golgi. Recently binding to Insig-1 was also shown to be important for the degradation of HMGR in response to sterols/MVA (29) . As with SCAP, the regulated interaction of HMGR with Insig-1 is thought to be mediated through the sterol-sensing domain in the membrane-embedded region of the enzyme (29) . Indeed transient overexpression of the membrane domain of SCAP impedes the regulated degradation of HMGR, indicating that the two proteins compete for 
TABLE II Apomine inhibits cholesterol esterification in cultured cells
The effect of Apomine on ACAT activity in cultured cells was determined in duplicate incubations as described under "Experimental Procedures." Results shown are the mean of three independent experiments. 
TABLE III Apomine does not inhibit cholesterol esterification in cell-free extracts
The effect of Apomine on ACAT activity in whole cell extracts from cells maintained in FCS-containing medium was determined in duplicate incubations as described under "Experimental Procedures." Results shown are the mean of three independent experiments. For comparison with Table II 
TABLE IV Effect of Apomine on LDLR activity
On day 1, CHO cells were plated in 24-well dishes in Medium A. On day 2, triplicate wells were refed with Medium B (''Control'') or Medium B supplemented with 1 M Apomine (''Apomine'') or 2 g/ml 25-hydroxycholesterol ϩ 20 g/ml cholesterol (''Sterols''). On day 3, the medium was removed, and the cells received 10 g/ml of the limiting amounts of Insig proteins (29, 56) . Since Apomine accelerates the rate of HMGR degradation, it stands to reason that Apomine, like sterols/MVA, strengthens the interactions between the membrane domain of HMGR and Insigs. These opposite effects of Apomine on the interactions with Insigs argue against the possibility that Apomine acts by mobilizing sterols from the plasma membrane or other intracellular pools to the cholesterol-poor ER membrane. Indeed, unlike 25-hydroxycholesterol, Apomine not only does not increase ACAT activity, but it actually inhibits it. Taken together, it appears that Apomine exploits divergent features of sterol-sensing domain-containing proteins and differentially affects their interactions with Insigs: it increases the affinity of HMGR to Insigs, leading to the rapid turnover of HMGR, but decreases the affinity of SCAP to Insigs, allowing the movement of SCAP⅐SREBP precursor out of the ER to the Golgi. The marked increase in HMGR levels in livers of Simvastatin-treated rats in efforts to overcome deficiency in MVA-derived products, suggests that the effects of statins may be limited and explains, in part, their lack of hypocholesterolemic activity in this animal model. Therefore, targeting HMGR for degradation is an attractive modality for the design of novel hypocholesterolemic drugs, especially for statin-resistant patients. However, such drugs should not be mimetics of oxysterols, such as 25-hydroxycholesterol, since the latter prevent cleavage of SREBP precursors and decrease LDLR activity, thereby preventing efficient clearance of LDL from the plasma. Indeed Apomine appears to fulfil these criteria: it potently stimulates HMGR degradation and in addition increases SREBP activation and LDLR activity. It should be noted that Apomine and other 1,1-bisphosphonate esters also activate the farnesoid X receptor (57, 58) and the pregnane X receptor (59) . The pharmacological consequences of activating these receptors by this class of compounds has yet to be investigated.
As critical aspects of the regulated degradation of HMGR are conserved from yeast to mammals (23) , Apomine possesses potent hypocholesterolemic activity in a variety of species, including rodents, hamsters, dogs, and cynomolgus monkeys. Apomine is well tolerated in preclinical toxicity studies and has an advantage of being highly bioavailable systemically in animals. 2 It is tempting to speculate that most of the previously observed activities of statins will also be exhibited by the 1,1-bisphosphonate esters. Thus, in addition to hypercholesterolemia, this class of compounds should be investigated as potential anticancer agents and in the treatment of osteoporosis and Alzheimer's disease. 
